Real-time disaster intelligence, alerts, and response tools.
Wednesday, April 29, 2026
[ad_1] Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market The availability of ZYMFENTRA will support greater patient access and choice while helping to drive […]
[ad_1] TAIPEI, Oct. 31, 2024 /PRNewswire/ — ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX) (“We”, “ASEH”, or the “Company”), the leading provider of semiconductor assembly and testing services (“ATM”) and the provider of electronic […]
[ad_1] BEIJING, Oct. 31, 2024 /PRNewswire/ — When Yong Yong (pseudonym) navigates through the bustling exhibition hall, a soothing voice whisperers in his ear, guiding him past obstacles and pointing out objects in his path. Wearing […]
[ad_1] LONDON, Oct. 31, 2024 /PRNewswire/ — Tetragon has released its Monthly Factsheet for September 2024. Net Asset Value: $3,016m Fully Diluted NAV Per Share: $33.85 Share Price (TFG NA): $10.20 Monthly NAV per share total […]
[ad_1] This approval marks the second international marketing authorization for sugemalimab outside of China, following its recent approval by the European Commission. The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, […]
